At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Giampaolo Bianchini, MD, of the San Raffaele Scientific Institute, Milan, Italy, explains that the specific setting and utility of a tumour biomarker must be clearly defined during clinical investigation in order to generate meaningful results. In patients with early stage breast cancer, there is a need to identify new risk factors for disease outcome, which may enable the identification of patients who are likely to respond to specific therapies.
This content is supported by Genomic Health, Inc.
European Medical Journal
Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews